NHS England has approved the use of Enhertu for breast cancer patients, providing access on the national health service to a drug that clinical data indicate can extend life by an average of seven months.
The antibody‑drug conjugate has already been prescribed and made available in Scotland for over two years. Its introduction in England expands access for patients across the UK to a treatment that had previously been restricted to Scottish services.
Medical authorities and health services will now implement prescribing arrangements so eligible patients can receive the drug through NHS pathways. The decision follows assessments of clinical benefit and is aimed at broadening treatment options for people with advanced breast cancer.
Advocates for improved cancer care have previously highlighted the importance of making new therapies available as evidence becomes established. The addition of Enhertu to the NHS in England marks a further step in the rollout of targeted treatments intended to improve survival and outcomes for patients with breast cancer.